Trials / Completed
CompletedNCT05357820
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
A Phase I, Single-center, Open-label, Fixed-sequence Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 Pharmacokinetics
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Nuvation Bio Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
AB-106-C110 is China-only study, for investigating the drug interaction between AB-106 and CYP3A4 inhibitor (Itraconazole)/CYP3A4 inducer (Rifampin)（n=56）
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AB-106, Itraconazole | single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17 |
| DRUG | AB-106, Rifampicin | single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21 |
Timeline
- Start date
- 2021-07-19
- Primary completion
- 2021-12-03
- Completion
- 2021-12-03
- First posted
- 2022-05-03
- Last updated
- 2024-11-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05357820. Inclusion in this directory is not an endorsement.